Huadong Medicine Co Ltd
SZSE:000963
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
62.7B CNY |
Loading...
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
120B USD |
Loading...
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
70.9B USD |
Loading...
|
|
| US |
|
Cencora Inc
NYSE:COR
|
71.1B USD |
Loading...
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
53.6B USD |
Loading...
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.8B AUD |
Loading...
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.7B USD |
Loading...
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.9B CNY |
Loading...
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
66.1B HKD |
Loading...
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
Loading...
|
|
| AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
7.1B USD |
Loading...
|
Market Distribution
| Min | -2 148% |
| 30th Percentile | 14.3% |
| Median | 23% |
| 70th Percentile | 34.6% |
| Max | 775.2% |
Other Profitability Ratios
Huadong Medicine Co Ltd
Glance View
Huadong Medicine Co., Ltd., a key player in China's pharmaceutical landscape, was established with a vision to integrate research, development, manufacturing, and distribution of pharmaceutical products. The company operates a diverse portfolio comprising prescription medicines, over-the-counter products, and active pharmaceutical ingredients. Central to its strategy is a robust focus on innovation and quality, enabling it to effectively cater to various therapeutic areas, including oncology, endocrinology, and nephrology. Huadong Medicine benefits from its substantial investment in research and development, with state-of-the-art facilities that drive advancements and partnerships with global biotech firms, thereby underscoring its commitment to bringing cutting-edge medical solutions to the market. At the heart of Huadong Medicine’s business model is a well-coordinated infrastructure that seamlessly blends manufacturing excellence with a sophisticated distribution network. This dynamic framework ensures the efficient delivery of products across China and into international markets, supporting a significant revenue stream. Additionally, the company's active pharmaceutical ingredients (API) division forms a crucial component of its operations, supplying high-quality raw materials to both domestic and international pharmaceutical companies. By maintaining a strategic balance between product innovation and operational efficiency, Huadong Medicine not only sustains its competitive advantage but also continually scales its presence in the global pharmaceutical industry, carving out a prominent niche in an increasingly competitive arena.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Huadong Medicine Co Ltd is 33.3%, which is above its 3-year median of 32.2%.
Over the last 3 years, Huadong Medicine Co Ltd’s Gross Margin has increased from 30.6% to 33.3%. During this period, it reached a low of 30.6% on Sep 30, 2022 and a high of 33.3% on Sep 30, 2025.